mTOR inhibitors: facing new challenges ahead

Related Experiment Video

Updated: Jun 1, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

I Mavrommati1, T Maffucci

  • 1Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute of Cell and Molecular Science, Centre for Diabetes, Inositide Signalling Group, London E1 2AT, UK.

Current Medicinal Chemistry
|June 9, 2011
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway is crucial in cancer, but inhibiting it has limited efficacy. Understanding mTOR pathway complexity is key to developing better anti-cancer strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Mammalian target of rapamycin (mTOR) is a key kinase regulating intracellular processes.
  • mTOR plays a critical role in cancer development and progression.
  • Inhibiting mTOR is a recognized anti-cancer therapeutic strategy, with ongoing clinical trials.

Purpose of the Study:

  • To review the current understanding of mTOR signaling in cancer.
  • To discuss the challenges and limitations in current mTOR inhibitor efficacy.
  • To explore how pathway complexity impacts the development of novel anti-cancer strategies targeting mTOR.

Main Methods:

  • Literature review of scientific publications and clinical trial results.
  • Analysis of the mTOR-dependent signaling pathway.
  • Discussion of resistance mechanisms and future therapeutic strategies.

Main Results:

  • Significant scientific literature exists on mTOR inhibitors in clinical trials.
  • Limited efficacy and resistance are major challenges in current mTOR-targeted cancer therapy.
  • The complexity of the mTOR pathway hinders the development of optimal therapeutic strategies.

Conclusions:

  • Despite its recognized role in cancer, the clinical efficacy of mTOR inhibitors is often limited.
  • Overcoming resistance requires a deeper understanding of the intricate mTOR signaling network.
  • Future strategies must address pathway complexity to fully leverage mTOR inhibition for cancer treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...